|
Name |
Tetratetracontane
|
| Molecular Formula | C44H90 | |
| IUPAC Name* |
tetratetracontane
|
|
| SMILES |
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
|
|
| InChI |
InChI=1S/C44H90/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39-41-43-44-42-40-38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h3-44H2,1-2H3
|
|
| InChIKey |
KMXFZRSJMDYPPG-UHFFFAOYSA-N
|
|
| Synonyms |
TETRATETRACONTANE; n-Tetratetracontane; 7098-22-8; FPX2NM4VIT; NSC-102262; Tetratetracontane, analytical standard; EINECS 230-407-0; NSC 102262; UNII-FPX2NM4VIT; Tetratetracontane, 99%; AI3-36493; DTXSID5058640; CHEBI:84289; ZINC6921186; MFCD00015268; NSC102262; AKOS015902653; AS-81740; Tetratetracontane, purum, >=95.0% (GC); FT-0753299; T72862; Q20890372; 1208B570-4CB6-48FD-9F3F-67129C995357; Tetratetracontane (C44) 1000 microg/mL in Carbon Disulfide
|
|
| CAS | 7098-22-8 | |
| PubChem CID | 23494 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 619.2 | ALogp: | 23.4 |
| HBD: | 0 | HBA: | 0 |
| Rotatable Bonds: | 41 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
| Heavy Atoms: | 44 | QED Weighted: | 0.047 |
| Caco-2 Permeability: | -5.91 | MDCK Permeability: | 0.00000024 |
| Pgp-inhibitor: | 0 | Pgp-substrate: | 0 |
| Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.008 |
| 30% Bioavailability (F30%): | 1 |
| Blood-Brain-Barrier Penetration (BBB): | 0 | Plasma Protein Binding (PPB): | 111.00% |
| Volume Distribution (VD): | 7.438 | Fu: | 0.24% |
| CYP1A2-inhibitor: | 0.005 | CYP1A2-substrate: | 0.073 |
| CYP2C19-inhibitor: | 0.043 | CYP2C19-substrate: | 0.041 |
| CYP2C9-inhibitor: | 0.001 | CYP2C9-substrate: | 0.992 |
| CYP2D6-inhibitor: | 0.001 | CYP2D6-substrate: | 0.002 |
| CYP3A4-inhibitor: | 0.045 | CYP3A4-substrate: | 0.002 |
| Clearance (CL): | 3.833 | Half-life (T1/2): | 0 |
| hERG Blockers: | 0.566 | Human Hepatotoxicity (H-HT): | 0.001 |
| Drug-inuced Liver Injury (DILI): | 0.602 | AMES Toxicity: | 0.012 |
| Rat Oral Acute Toxicity: | 0.003 | Maximum Recommended Daily Dose: | 0.091 |
| Skin Sensitization: | 0.993 | Carcinogencity: | 0.005 |
| Eye Corrosion: | 0.998 | Eye Irritation: | 0.919 |
| Respiratory Toxicity: | 0.063 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000541 | ![]() |
0.908 | D00AOJ | ![]() |
0.459 | ||
| ENC001153 | ![]() |
0.813 | D00STJ | ![]() |
0.326 | ||
| ENC001204 | ![]() |
0.793 | D01NTX | ![]() |
0.322 | ||
| ENC000438 | ![]() |
0.792 | D0Z1QC | ![]() |
0.316 | ||
| ENC000576 | ![]() |
0.769 | D06KDP | ![]() |
0.314 | ||
| ENC000565 | ![]() |
0.730 | D00FGR | ![]() |
0.297 | ||
| ENC000381 | ![]() |
0.723 | D07ILQ | ![]() |
0.293 | ||
| ENC003062 | ![]() |
0.701 | D0Z5SM | ![]() |
0.260 | ||
| ENC000437 | ![]() |
0.700 | D05ZPL | ![]() |
0.253 | ||
| ENC001249 | ![]() |
0.682 | D0T9TJ | ![]() |
0.246 | ||